Eli Lilly Makes Another In Vivo Genetic Medicines Move With $3.2B Kelonia Acquisition

Eli Lilly acquired Kelonia Therapeutics for $3.2 billion to add an in vivo cell therapy program targeting multiple myeloma. The deal marks Lilly's third genetic medicines acquisition in as many years, following purchases of Verve and Orna Therapeutics, as the pharmaceutical giant diversifies its approach to in vivo genetic therapy across multiple platforms and disease targets.